Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
Abstract Background Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells. Although these agents extend progression-free survival in many patients, responses can be short lived...
Main Authors: | Shane O’Brien, Michael Butticello, Christine Thompson, Boris Wilson, Anastasia Wyce, Vivek Mahajan, Ryan Kruger, Helai Mohammad, Andy Fedoriw |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-11260-z |
Similar Items
-
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
by: Stephanie Jonuscheit, et al.
Published: (2021-05-01) -
Effects of the PARP inhibitor Niraparib on the radiosensitivity of human lung and cervical cancer cells
by: Yue Feng, et al.
Published: (2023-06-01) -
Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
by: Mauro Francesco Pio Maiorano, et al.
Published: (2023-09-01) -
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
by: José Yélamos, et al.
Published: (2020-02-01) -
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)